Remaining and new challenges despite of dazzling news in RCC
•
It’s frustrating we lack any robust biomarkers for anything so far
•
What’s the current and future role of cytoreductive nephrectomy?
•
If sunitinib becomes standard in the adjuvant setting which one is next?
•
How should we address intratumour heterogeneity in the clinic?
•
If IOs +/- antiangiogenics become standard in 1
st
line what would it be our choice
in 2
nd
line?
•
There will be a winner among PD1 axis inhibitors?
